BiotechTube
Nitto BioPharma

Nitto BioPharma

San Diego, United States· Est.
nittobiopharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Nitto BioPharma is a specialized drug delivery company founded in 2016 as the U.S. R&D arm of Japan's Nitto Denko Corporation. It is headquartered in San Diego and operates at the forefront of nucleic acid delivery, with core expertise in designing novel, biodegradable lipid nanoparticle (LNP) and polymer-based delivery vehicles. The company functions primarily as a platform and partnership-driven business, offering its delivery technologies and program development capabilities to collaborators to advance cutting-edge genetic medicines. Its strategy is centered on licensing its proprietary platforms and co-developing programs with pharmaceutical partners.

Drug DeliveryRNA & Gene Therapy

Technology Platform

Proprietary lipid nanoparticle (LNP) and polymer-based delivery systems for nucleic acids. Platform features novel biodegradable lipids from >15 families, expertise in nucleic acid design, and proprietary formulations for targeted, efficient delivery of siRNA, mRNA, and gene editing cargo.

Opportunities

The company is positioned to capitalize on the massive growth in RNA and gene therapy markets by providing essential, next-generation delivery technology.
Its focus on biodegradable and targeted LNPs addresses key unmet needs for extrahepatic delivery, creating high-value partnership potential across multiple therapeutic areas.

Risk Factors

Intense competition in the drug delivery space from both biotech and large pharma poses a significant risk.
Technical challenges in achieving efficient and safe delivery beyond the liver remain, and the company's success is entirely dependent on securing and advancing collaborative partnerships, which carries inherent business and scientific risk.

Competitive Landscape

Nitto BioPharma competes in a crowded field of drug delivery specialists, including companies like Arcturus Therapeutics, ReCode Therapeutics, and GenEdit, as well as the internal delivery efforts of large RNA/biotech firms like Alnylam, Moderna, and BioNTech. Differentiation hinges on demonstrating superior targeting, biodegradability, and efficacy with its proprietary lipid libraries.

More companies in Drug Delivery & Formulation →More companies in United States →